LAUSR

Epithelial ovarian cancer consists of several histological subtypes including low versus high grade serous, clear cell, endometrioid, and mucinous adenocarcinomas. These cell types have different patient demographics, carcinogenesis, molecular alterations, clinical presentations and prognoses [1]. Clear cell cancer patients are more likely to present at a younger age, have earlier stage of disease, be found in Asians, and associated with endometriosis and thromboembolic events. [2] However, there is still significant controversy on the prognostic difference of clear cell versus other epithelial ovarian cancer. Large national and international cancer registry reports have shown worse outcomes for clear cell cancer patients. [2–4] However, these studies were limited by: inconsistent comprehensive surgical staging or optimal cytoreductive surgery, lack of central pathology review, nonuniform use of standard front line chemotherapy and routine followup. The use of ancillary data from oncology group trials may minimize some of these concerns. [5]